Trial Profile
Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Selumetinib (Primary)
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Dec 2021 Planned End Date changed from 1 Aug 2026 to 30 Aug 2026.
- 29 Dec 2021 Planned primary completion date changed from 1 Aug 2026 to 30 Aug 2026.